Henry Schein ( (HSIC) ) has released its Q1 earnings. Here is a breakdown of the information Henry Schein presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Henry Schein, Inc. is a leading provider of health care solutions for office-based dental and medical practitioners, operating in the health care distribution industry with a vast network of products and services.
In its first quarter of 2025, Henry Schein reported a significant increase in its GAAP diluted earnings per share (EPS), showing a 22% growth compared to the same period in 2024. The company also maintained its financial guidance for the year, indicating steady expectations for sales and earnings growth.
Key financial highlights include a total net sales figure of $3.2 billion, with a slight decrease of 0.1% in as-reported sales due to currency fluctuations. However, constant currency sales excluding PPE and COVID test kits showed a 2.0% growth. The company also repurchased $161 million worth of common stock, reflecting its commitment to returning value to shareholders.
Henry Schein’s strategic initiatives, such as the BOLD+1 Strategic Plan, focus on enhancing operational efficiency, expanding its digital footprint, and growing its specialty businesses. The company recorded $25 million in restructuring costs and aims to achieve significant annual savings by the end of 2025.
Looking ahead, Henry Schein remains optimistic about its growth prospects, with expectations of mid-single-digit adjusted EBITDA growth and continued sales expansion, supported by its strategic initiatives and operational efficiencies.